![]() |
市場調查報告書
商品編碼
2170202
血液透析導管市場機會、成長要素、產業趨勢分析及2026-2035年預測Hemodialysis Catheters Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035 |
||||||
預計到 2025 年,血液透析導管市場規模將超過 10.6 億美元,年複合成長率為 6.9%,到 2035 年將達到 20.6 億美元。
這些裝置為腎臟替代療法提供血管通路,並有多種配置可供選擇,例如即時用型和長期使用型。採購趨勢反映了醫療服務提供者的需求,例如是否需要啟動透析、是否需要永久性通路、是否能確保可靠的血流、是否易於插入以及是否與既定的導管管理方案相容。
| 市場範圍 | |
|---|---|
| 開始年份 | 2025 |
| 預測期 | 2026-2035 |
| 上市時的市場規模 | 10.6億美元 |
| 預計金額 | 20.6億美元 |
| 複合年成長率 | 6.9% |
末期腎病持續推動醫院和門診透析服務機構的導管採購。成熟的腎臟護理系統透過接受治療的患者持續購買導管,而隨著更多患者進入正規透析流程,不斷擴張的系統也增加了導管需求。亞太地區基礎設施的建設促進了透析網路的批量採購,而持續的報銷和不斷增加的設施也影響著患者獲得治療的機會。在動靜脈瘻管或移植血管可用之前,當需要透析時,導管也發揮「橋樑」的作用。轉診、血管通路規劃和動靜脈瘻管成熟的延遲會延長透析需求,從而推高了對急性照護導管和隧道導管的需求。在產品開發方面,透過適用於感染控制措施的導管尖端設計和抗菌表面技術,正在建立以價值為導向的採購管道。醫療服務提供者重視這些特性,以及血流可靠性和插入效率。因此,商業性機會結合了持續的血管通路需求和選擇性升級,導管性能和標準化護理方案會影響醫療服務提供者的採購決策。
根據導管類型,預計到2025年,長期血液透析導管的市場規模將達到6.38億美元。部分患者在急性治療期後仍需維持血管通路,因此需要能支持長期使用的導管。安全形成血管通路和易於操作的置入是其適用性的關鍵因素,尤其是在門診透析中。在永久性血管通路尚未普及的情況下,這些產品將繼續發揮至關重要的作用。進入該領域的供應商需要根據臨床操作和醫療機構的工作流程來調整導管的特性,而不僅僅是強調使用時間長度。可靠的血管通路和持續透析的實際需求是推動採購的主要因素,而醫療機構的偏好和既定的導管護理規範則影響著該長期使用產品類型中的選擇。
單獨來看,帶袖隧道導管預計到2025年銷售額將達4.36億美元。袖套周圍的組織生長有助於導管的穩定性,並能有效阻止污染物在導管內擴散。這些特性使其適用於計畫內的長期通路。然而,實際應用的可行性仍取決於現有的手術能力、個別解剖結構以及透析中心的偏好。客戶會根據導管插入和護理操作來評估產品,這些操作和操作需要支援持續治療。因此,在商業性提案中,導管的設計及其在長期使用中的通路管理能力是緊密相關的。當醫療機構優先考慮計劃內的導管插入路徑以及與既定感染預防措施的兼容性時,供應商可以透過提供合適的配置和可靠的性能來贏得競爭優勢。
預計2025年,北美血液透析導管市場規模將達到4.46億美元。成熟的透析服務和完善的保險報銷系統為大規模腎臟護理機構和醫院的採購提供了支援。儘管通路規劃和感染監測會影響需求,但醫療保健採購仍需可靠的供應和臨床證據。供應商必須滿足標準化的選擇標準,而不能僅依賴醫生的偏好或產品的新穎性。與主要醫療機構和採購組織建立關係對於確定客戶管道至關重要。因此,該地區的商業機會受制於持續的治療需求和正式的評估流程,供應商競相滿足導管的性能要求和成熟透析網路的營運預期。
預計到2025年,Teleflex將佔據約19%的市場。其「Arrow」血管通路產品系列可滿足急性和慢性導管需求,產品注重抗菌性能和卓越表現。公司憑藉其在血管通路領域的專業知識和廣泛的醫院網路,確保能夠透過多種採購管道獲得產品。其專注於血管通路業務的產品組合策略,凸顯了導管領域創新和執行力的商業性重要性。憑藉其穩固的業務基礎,Teleflex能夠滿足客戶當前和持續的血管通路需求,並佔據市場領先地位。客戶在評估醫療設備性能和醫療機構供應鏈時,可以將Teleflex豐富的產品線納入更廣泛的採購決策考量,其中,證據、產品範圍和可靠的生產能力都會影響供應商的選擇。
市場的主要參與者包括BD、B. Braun、AngioDynamics、Baxter、Cook Medical、Mozarc Medical、Merit Medical、Vygon、Medcomp、Healthline Medical Products、ST Stone Medical、Bain Medical Equipment、Delta Med、Polymed和Amecath。 BD透過其多樣化的導管設計和國際分銷網路,滿足急性和慢性血管通路需求。 B. Braun將血管通路與廣泛的腎臟護理產品相結合,而專業公司則專注於血流性能、介入應用和區域性需求。區域性競爭對手透過縮短供應鏈和提供具有成本效益的產品,在價格和供應方面保持競爭力。醫院評估團隊、採購集團和透析網路在選擇導管供應商時,會考慮產品的科學基礎、感染控制措施、生產可靠性以及與供應商的廣泛合作關係。
The Hemodialysis Catheters Market exceeded USD 1.06 billion in 2025 and is projected to grow at 6.9% CAGR to reach USD 2.06 billion by 2035. Devices provide vascular access for renal replacement therapy, including immediate-use and longer-term configurations. Purchasing reflects dialysis initiation, availability of permanent access, and providers' requirements for dependable flow, practical insertion, and compatibility with established catheter-care protocols.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $1.06 Billion |
| Forecast Value | $2.06 Billion |
| CAGR | 6.9% |
End-stage kidney disease sustains catheter procurement across hospitals and outpatient dialysis services. Established renal-care systems generate recurring purchasing from patients already receiving treatment, while expanding systems add demand as more patients enter formal dialysis pathways. Asia Pacific infrastructure growth supports bulk procurement by dialysis networks, with reimbursement continuity and additional centers influencing access to treatment. Catheters also serve as a bridge when dialysis is required before a fistula or graft can be used. Delayed referral, access planning, and fistula maturation can extend that need, supporting both acute and tunneled configurations. Product development adds a value-driven purchasing channel through tip design and antimicrobial surface technologies suited to infection-control practice. Facilities evaluate these features alongside flow reliability and insertion efficiency. The commercial opportunity consequently combines persistent access requirements with selective upgrades where catheter performance and standardized care protocols influence institutional buying decisions.
Based on catheter type, long-term hemodialysis catheters contributed USD 638 million in 2025. Patients requiring access beyond an acute treatment period create a role for devices that can support extended use. Secure tunneling and manageable dwell performance influence their suitability, particularly in outpatient dialysis. These products remain relevant while permanent vascular access is unavailable. Suppliers serving the segment need to align device characteristics with clinical handling and provider workflows rather than emphasize duration alone. Dependable access and the practical requirements of ongoing dialysis support purchasing, while facility preferences and established catheter-care approaches shape selection within this longer-term product category.
By product, cuffed tunneled catheters contributed revenue of USD 436 million in 2025. Tissue growth around the cuff helps stabilize the device and provides a barrier to contamination moving along the catheter. These properties support use in planned longer-term access pathways. Adoption still depends on the procedure capabilities available, individual anatomy, and dialysis-center preferences. Customers evaluate the product within insertion and care practices that must support continued treatment. The commercial proposition therefore connects device design with the ability to manage access over extended use. Suppliers can compete through suitable configurations and reliable performance where providers prioritize planned catheter pathways and compatibility with established infection-prevention routines.
The North America hemodialysis catheters market contributed USD 446 million in 2025. Mature dialysis services and established reimbursement support purchasing by large renal-care organizations and hospitals. Access planning and infection surveillance influence demand, while institutional procurement creates requirements for dependable supply and clinical evidence. Vendors must meet standardized selection criteria rather than rely solely on physician preference or product novelty. Relationships with major care providers and purchasing organizations help determine account access. The regional opportunity is consequently shaped by recurring treatment needs and formal evaluation processes, with suppliers competing to satisfy both catheter performance requirements and the operational expectations of established dialysis networks.
Teleflex held approximately 19% market share in 2025. Its Arrow vascular-access range covers acute and chronic catheter needs alongside antimicrobial and performance-oriented offerings. The company combines vascular-access knowledge with broad hospital reach, giving it access to several procurement settings. Portfolio actions focusing attention on businesses that include vascular access reinforce the commercial importance of catheter innovation and execution. Its position reflects the ability to serve immediate and continuing access requirements through an established franchise. Customers evaluating device performance and institutional supply can consider this breadth within broader purchasing decisions, where evidence, product range, and dependable manufacturing influence supplier selection.
Some of the major players in this market are BD, B. Braun, AngioDynamics, Baxter, Cook Medical, Mozarc Medical, Merit Medical, Vygon, Medcomp, Healthline Medical Products, ST Stone Medical, Bain Medical Equipment, Delta Med, Polymed, and Amecath. BD serves acute and chronic access through varied catheter designs and international distribution. B. Braun connects vascular access with a wider renal-care portfolio, while specialist companies address flow performance, interventional use, and local requirements. Regional competitors sustain price and availability competition through shorter supply chains and cost-conscious offerings. Hospital evaluation teams, purchasing groups, and dialysis networks consider product evidence, infection-control positioning, manufacturing reliability, and broader supplier relationships when choosing catheter providers.